Cassava Sciences, Inc. SAVA
1.32 USD 0.00 (+0.00%)
May 22, 2026, 12:35 PM EDT
1.27 Day range 1.35
2.23 52-week range 42.20
- YTD
- -33.33%
- 1 year
- -25.42%
- Market cap
- 115.95M
- EPS (ttm)
- -1.38
- Shares out
- 48.11M
- Forward P/E
- -1.36
- YTD return
- -33.33%
- 1-year return
- -25.42%
- Volume
- 134.26K
- Avg volume
- 5.19M
- Open
- 1.30
- Previous close
- 1.32
- Day's range
- 1.27 – 1.35
- 52-week range
- 2.23 – 42.20
- Beta
- -0.58
YTD 0.00 (0.00%)
Key statistics
- Enterprise value
- -35.92M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -82.64M
- Total cash
- 148.98M
- Total debt
- 0
- Return on equity
- -10.98%
- Short % of float
- 38.06%
- 50-day average
- 17.99
- 200-day average
- 21.09
Analyst view
Price target (mean) —
Ratings (0m) 2 0 buy · 2 hold · 0 sell
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.68.
Financials — quick view
SAVA Revenue — quarterly 0
SAVA Net income — quarterly -10.81M
SAVA EPS — quarterly -0.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.37 | -0.58 | +0.79 | +57.66% |
| Aug 8, 2024 | Jun 1, 2024 | -0.44 | -1.28 | -0.84 | -190.91% |
| May 10, 2024 | Mar 1, 2024 | -0.51 | -1.41 | -0.90 | -176.47% |
| Feb 28, 2024 | Dec 1, 2023 | -0.40 | -0.50 | -0.10 | -25.00% |
| Nov 7, 2023 | Sep 1, 2023 | -0.90 | -0.61 | +0.29 | +32.22% |
| Aug 3, 2023 | Jun 1, 2023 | -0.58 | -0.63 | -0.05 | -8.62% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 8, 2024 | HC Wainwright & Co. | up | Neutral | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Aug 8, 2024 | Rodman & Renshaw | reit | Buy | Buy |
| Jul 19, 2024 | HC Wainwright & Co. | reit | — | Neutral |
About Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cassavasciences.com
News
12 Health Care Stocks Moving In Wednesday's After-Market Session 
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS 
Cassava Announces Agreement to Settle Securities Class Action Litigation 
12 Health Care Stocks Moving In Friday's Intraday Session 
FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold - 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM) 
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Your note
Sign in to keep a note on SAVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARBIER REMI | Chief Executive Officer | Conversion of Exercise of derivative security | May 23, 2023 | 0 |
| BARRY RICHARD J | Director | Conversion of Exercise of derivative security | Apr 22, 2024 | 0 |
| GUSSIN ROBERT Z | Director | Conversion of Exercise of derivative security | Apr 30, 2023 | 10,617 |
| KUPIEC JAMES WILLIAM | Officer | Sale | Nov 28, 2024 | 0 |
| O DONNELL MICHAEL J | Director | Conversion of Exercise of derivative security | Mar 6, 2023 | 6,873 |
| ROBERTSON SANFORD R | Director | Stock Gift | May 15, 2024 | 1,135,850 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.78% | 3,263,474 | 7.86M | Sep 29, 2024 |
| Vanguard Group Inc | 5.24% | 2,522,798 | 6.08M | Sep 29, 2024 |
| State Street Corporation | 2.42% | 1,162,749 | 2.80M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.10% | 1,008,593 | 2.43M | Sep 29, 2024 |
| Gallacher Capital Management LLC | 1.21% | 580,042 | 1.40M | Sep 29, 2024 |
| Morgan Stanley | 1.08% | 519,544 | 1.25M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.65% | 1,275,948 | 3.08M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.17% | 1,045,518 | 2.52M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.41% | 678,626 | 1.64M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.86% | 415,510 | 1.00M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.75% | 362,957 | 874.73K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.52% | 251,560 | 606.26K | Oct 30, 2024 |